Avanos Medical (NYSE:AVNS) Sets New 1-Year Low - Should You Sell?

Avanos Medical, Inc. (NYSE:AVNS - Get Free Report)'s stock price hit a new 52-week low on Monday . The stock traded as low as $11.90 and last traded at $12.26, with a volume of 458797 shares changing hands. The stock had previously closed at $12.06.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.

Avanos Medical Trading Up 0.6 %

The stock has a 50 day moving average price of $14.15 and a 200-day moving average price of $16.92. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $575.04 million, a PE ratio of 36.76 and a beta of 1.15.

Avanos Medical (NYSE:AVNS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The company had revenue of $179.60 million for the quarter, compared to the consensus estimate of $177.23 million. Sell-side analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Insider Activity at Avanos Medical

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the completion of the transaction, the senior vice president now owns 82,047 shares of the company's stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its position in shares of Avanos Medical by 35.8% during the 3rd quarter. Jane Street Group LLC now owns 65,650 shares of the company's stock worth $1,578,000 after purchasing an additional 17,306 shares in the last quarter. Barclays PLC raised its stake in Avanos Medical by 446.2% during the third quarter. Barclays PLC now owns 96,194 shares of the company's stock valued at $2,311,000 after buying an additional 78,583 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Avanos Medical by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company's stock valued at $25,337,000 after buying an additional 16,065 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Avanos Medical by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company's stock valued at $1,672,000 after purchasing an additional 4,472 shares during the period. Finally, Tributary Capital Management LLC increased its holdings in shares of Avanos Medical by 38.1% during the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company's stock valued at $14,217,000 after purchasing an additional 246,379 shares during the period. Hedge funds and other institutional investors own 95.17% of the company's stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.